WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that Chairman and Chief Executive Officer Jonathan Javitt, M.D., M.P.H., will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 p.m. ET.
The company said a live webcast and replay of the session will be made available through its investor relations site. Management will also meet with investors in one-on-one sessions during the conference.
NRx is a clinical-stage biopharmaceutical company focused on therapies for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. Its lead programs include NRX-100, an intravenous ketamine treatment that has received Fast Track designation from the FDA, and NRX-101, an oral therapy that has been granted Breakthrough Therapy designation for suicidal bipolar depression. The company has also advanced regulatory filings for NRX-100, including an Abbreviated New Drug Application and a New Drug Application under the Commissioner’s National Priority Voucher Program.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.